Clonazepam treatment of tardive dyskinesia

A practical GABAmimetic strategy

Gunvant K. Thaker, James A. Nguyen, Milton E. Strauss, Richard Jacobson, Bruce A. Kaup, Carol A. Tamminga

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Because of the efficacy of specific γ-aminobutyric acid (GABA) agonists in tardive dyskinesia, the authors tested the benzodiazepine clonazepam in a 12-week, double-blind, placebo-controlled, randomized crossover trial in 19 chronically ill patients with tardive dyskinesia who were being treated with neuroleptics. They found a 35% decrease in dyskinesia ratings with clonazepam treatment. The six patients with predominantly dystonic symptoms showed greater benefit than the 13 patients with predominantly choreoathetoid dyskinesias. Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week donazepam-free period recaptured its antidyskinetic effect.

Original languageEnglish (US)
Pages (from-to)445-451
Number of pages7
JournalAmerican Journal of Psychiatry
Volume147
Issue number4
StatePublished - 1990

Fingerprint

Clonazepam
Dyskinesias
GABA Agonists
Aminobutyrates
Therapeutics
Benzodiazepines
Cross-Over Studies
Antipsychotic Agents
Chronic Disease
Placebos
Tardive Dyskinesia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Thaker, G. K., Nguyen, J. A., Strauss, M. E., Jacobson, R., Kaup, B. A., & Tamminga, C. A. (1990). Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. American Journal of Psychiatry, 147(4), 445-451.

Clonazepam treatment of tardive dyskinesia : A practical GABAmimetic strategy. / Thaker, Gunvant K.; Nguyen, James A.; Strauss, Milton E.; Jacobson, Richard; Kaup, Bruce A.; Tamminga, Carol A.

In: American Journal of Psychiatry, Vol. 147, No. 4, 1990, p. 445-451.

Research output: Contribution to journalArticle

Thaker, GK, Nguyen, JA, Strauss, ME, Jacobson, R, Kaup, BA & Tamminga, CA 1990, 'Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy', American Journal of Psychiatry, vol. 147, no. 4, pp. 445-451.
Thaker, Gunvant K. ; Nguyen, James A. ; Strauss, Milton E. ; Jacobson, Richard ; Kaup, Bruce A. ; Tamminga, Carol A. / Clonazepam treatment of tardive dyskinesia : A practical GABAmimetic strategy. In: American Journal of Psychiatry. 1990 ; Vol. 147, No. 4. pp. 445-451.
@article{c39169c0231d485e90b6a96ff7b7f845,
title = "Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy",
abstract = "Because of the efficacy of specific γ-aminobutyric acid (GABA) agonists in tardive dyskinesia, the authors tested the benzodiazepine clonazepam in a 12-week, double-blind, placebo-controlled, randomized crossover trial in 19 chronically ill patients with tardive dyskinesia who were being treated with neuroleptics. They found a 35{\%} decrease in dyskinesia ratings with clonazepam treatment. The six patients with predominantly dystonic symptoms showed greater benefit than the 13 patients with predominantly choreoathetoid dyskinesias. Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week donazepam-free period recaptured its antidyskinetic effect.",
author = "Thaker, {Gunvant K.} and Nguyen, {James A.} and Strauss, {Milton E.} and Richard Jacobson and Kaup, {Bruce A.} and Tamminga, {Carol A.}",
year = "1990",
language = "English (US)",
volume = "147",
pages = "445--451",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Clonazepam treatment of tardive dyskinesia

T2 - A practical GABAmimetic strategy

AU - Thaker, Gunvant K.

AU - Nguyen, James A.

AU - Strauss, Milton E.

AU - Jacobson, Richard

AU - Kaup, Bruce A.

AU - Tamminga, Carol A.

PY - 1990

Y1 - 1990

N2 - Because of the efficacy of specific γ-aminobutyric acid (GABA) agonists in tardive dyskinesia, the authors tested the benzodiazepine clonazepam in a 12-week, double-blind, placebo-controlled, randomized crossover trial in 19 chronically ill patients with tardive dyskinesia who were being treated with neuroleptics. They found a 35% decrease in dyskinesia ratings with clonazepam treatment. The six patients with predominantly dystonic symptoms showed greater benefit than the 13 patients with predominantly choreoathetoid dyskinesias. Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week donazepam-free period recaptured its antidyskinetic effect.

AB - Because of the efficacy of specific γ-aminobutyric acid (GABA) agonists in tardive dyskinesia, the authors tested the benzodiazepine clonazepam in a 12-week, double-blind, placebo-controlled, randomized crossover trial in 19 chronically ill patients with tardive dyskinesia who were being treated with neuroleptics. They found a 35% decrease in dyskinesia ratings with clonazepam treatment. The six patients with predominantly dystonic symptoms showed greater benefit than the 13 patients with predominantly choreoathetoid dyskinesias. Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week donazepam-free period recaptured its antidyskinetic effect.

UR - http://www.scopus.com/inward/record.url?scp=0025264442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025264442&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 445

EP - 451

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -